Columns, Fall Down, Get Up Again- a Column by John Connor I’m an Old Hand at Dealing with MS Mishaps

Columns, The MS Wire - A Column by Ed Tobias Neuros Say that Flu Shots and Other Vaccines Are OK for Those with MS

News, SPMS #ECTRIMS2019 – Mayzent’s Benefits from a Patient Perspective a ‘Key Question,’ Says EXPAND’s Principal Investigator

News #ECTRIMS2019 – Ahead for Mavenclad: Fuller Understanding of What Makes It ‘Unique,’ Serono Exec Says in Interview

Columns, MS in Moderation, a column by Tamara Sellman Need to Know: What Is the JC Virus?

Columns, Silver Linings - a Column by Jennifer Powell Emotionally Hard-wired: Pseudobulbar Affect and MS

News JK Rowling Donates £15.3M to UK Clinic Working in MS Research, Treatment Discovery

News #ECTRIMS2019 – Ocrevus Living Up to ‘Game-changing’ Moniker, Genentech’s Hideki Garren Says in Interview

News #ECTRIMS2019 – Cell Immunotherapy ATA188 Showing Safety, Hints of Effectiveness in Progressive MS in Phase 1 Trial

News #ECTRIMS2019 – Ozanimod’s ‘Key Advantages’ May Lead to New First-line MS Therapy: Interview with Neurologist Jeffrey Cohen

News, SPMS #ECTRIMS2019 — Ponesimod Superior to Aubagio in Relapsing MS, OPTIMUM Trial Shows

News, SPMS #ECTRIMS2019 – Data Shows Ublituximab’s Long-term Safety in Relapsing MS, TG Therapeutics Announced

News FTC Warns Companies Against Unsubstantiated Advertising of CBD Products for MS

News #ECTRIMS2019 – Acthar Gel Seen as Cost-effective Late-line Treatment Option for MS Relapses

Columns, Patiently Awakened - A Column by Teresa Wright-Johnson My Judgment-free Zone

News #ECTRIMS2019 – Tysabri During Pregnancy and After Delivery Seems Safe, Reduces Relapse Risk, Study Finds

News, SPMS #ECTRIMS2019 — Ofatumumab Superior to Aubagio in Lowering Relapse Rates and Lesions, Data Show

News, Ocrevus #ECTRIMS2019 – Early Ocrevus Use Slows Disability in PPMS, Including Risk of Wheelchair Reliance

News #ECTRIMS2019 – Age Seen as Crucial in MS Outcomes, with 40 Marking Shift from Relapses to Progression

News #ECTRIMS2019 – Relapses Tied to Greater Medical and Personal Costs in Real-world Data

News #ECTRIMS2019 — Glia Score May Differentiate Progressive MS from RRMS, Study Suggests

News, SPMS #ECTRIMS2019 – Mayzent Reduces Risk of SPMS Patients Becoming Wheelchair Bound, Data Show

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Stem Cell Transplants, Remyelination Agent, Tecfidera Study, Plasma Exchange and Tysabri-linked PML

News #ECTRIMS2019 – Nerve Cell Damage May Be Evident Years Before Symptoms Are

News #ECTRIMS2019 – Newer DMTs More Effective Than Older Injectables in Pediatric MS, Study Says

News #ECTRIMS2019 – Anti-epileptic May Help to Stop Disability Progression, Study Suggests

Columns, Fall Down, Get Up Again- a Column by John Connor Going Mobile, Part 2: I’m Powering Around the House

News #ECTRIMS2019 — Eliminating SARM1 Protects Neurons in Mouse Model of MS

Columns, The MS Wire - A Column by Ed Tobias Stem Cell Program That Treated Selma Blair Closes Its Doors

News #ECTRIMS2019 — Human Herpesvirus 6A May Increase MS Risk, Study Suggests

News, SPMS #ECTRIMS2019 – Mesenchymal Stem Cell Transplants Safe and Help Stop Progressive MS, Trial Data Show

News #ECTRIMS2019 – Younger MS Patients at Higher Risk for Cardiovascular Diseases, Large Swedish Study Finds

News, SPMS #ECTRIMS2019 – Longer DMT Use and Female Sex Seen to Protect Against SPMS Conversion

Columns, MS in Moderation, a column by Tamara Sellman Need to Know: Should I Disclose My MS at Work?

Columns, Silver Linings - a Column by Jennifer Powell We All Have Bad Days

News #ECTRIMS2019 — Biogen Presents New Real-world Data Demonstrating Clinical Benefits of Tysabri, Plegridy, and Avonex

News #ECTRIMS2019 — Promises and Warnings About Stem Cell Therapy

News #ECTRIMS2019 – No Retinal Thinning with Ocrevus in Relapsing MS Patients, Phase 3 Trials Show

News, Ocrevus #ECTRIMS2019 – 6 Years of Ocrevus Use Tied to Low Rates of Serious Infections

News #ECTRIMS2019 – Plasma Exchange Ineffective for Treating Tysabri-associated PML, Study Shows

News #ECTRIMS2019 – Remyelinating Therapy Liothyronine Well-tolerated by MS Patients, Phase 1b Trial Finds

News #ECTRIMS2019 – 10-year Data Confirm Long-term Benefits of Biogen’s Tecfidera for RRMS

Columns, MSunderstood Millennial - a Column by Stephanie Towler I Struggle with Sleep Disorders, but They Don’t Stop Me

News #ECTRIMS2019 – MS Patients Should Be Informed about Pregnancy Risks and Family Planning, Experts Say

News #ECTRIMS2019 – Real-world Data Supports Serum Neurofilament Light as Potential MS Biomarker

Alexa, News, SPMS SPMS Triggers and Treatments Among Focus of Expert Panel in Video Series by AJMC

News NervGen Planning Clinical Trials of NVG-291, Peptide That Might Promote Myelin Repair

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Cancer Medication Slows MS, Vitamin D and Myelin, Targeting ‘Helper’ T-cells, Vaccination Guidelines

News Inflammation Hijacks Myelin Repair Cells to Promote Immune Attacks, Study Shows

News #ECTRIMS2019 – Mapi Pharma to Detail Latest Trial Data on GA Depot in Treating RRMS and PPMS

A Life in Letters -- A Column By Jamie Hughes, Columns I Did Not See That (Ulcer) Coming

Columns, Fall Down, Get Up Again- a Column by John Connor Under Pressure

Columns, The MS Wire - A Column by Ed Tobias Social Cognition: Does It Impact MS Symptoms?

News Oral Ozanimod More Effective Than Avonex in Lowering Annual Relapses in MS Patients, Phase 3 Trial Finds

News MS Advocate Cathy Tolk Opens Website, Sharing Motivational Thoughts with Others Near and Far

Columns, MS in Moderation, a column by Tamara Sellman Need to Know: Expanding Your MS Symptom Journal

Columns, Silver Linings - a Column by Jennifer Powell Becoming Your Own Advocate Takes Practice, but It’s Worth It

News Floodlight App Gets Positive Ratings, Shows Good Continuous Use in Pilot Study

News Sandoz Enters Agreement with Polpharma Biologics to Develop and Commercialize Tysabri Biosimilar

Columns, Making a Difference - a Column by Cathy Chester. Ageism in Clinical Trials and Healthcare

News MS Relationships Improved by Togetherness and Communication, Study Suggests

News Targeting Inflammatory Th17 Cells to Slow MS Disability Possible with Fewer Side Effects, Study Suggests

News Poorer Social Cognition Linked to Worse Fatigue, Depression, and Anxiety in People with MS

News Ofatumumab Better at Easing Relapse Rates and Slowing MS Progression Than Aubagio, Phase 3 Data Show

Sponsored Content When your brain is injured or damaged, it has a natural ability to adapt ...

Columns, Fall Down, Get Up Again- a Column by John Connor My Disabled Wheelchair

Columns, The MS Wire - A Column by Ed Tobias Another Study Shows That Costs of Disease-modifying Therapies Are Zooming

News New AAN Guidelines Favor Regular Vaccinations, Including Flu Shots, for MS Patients

News Higher Vitamin D Levels May Promote ‘Myelin Integrity’ in Progressive MS, Study Suggests

Columns, MS in Moderation, a column by Tamara Sellman Need to Know: What Is a Symptom Journal?

News Therapy Costs Increase More Than Sevenfold for MS Patients on Medicare, 10-Year Study Reveals

News Role of SARM1 Enzyme, Key Player in Neurodegeneration, Detailed in Studies

News Mavenclad Cost-Effective Treatment for At-risk RRMS Patients Compared to Other DMTs, Dutch Study Finds

News MS Fatigue Linked to 3 Different Patterns of Physical Activity, Study Finds

Columns, The MS Wire - A Column by Ed Tobias I Dreamed That I Was Walking

News Central Vein Sign Maintains Potential as MS Diagnostic Marker, European Study Shows

News Phase 1 Clinical Trial of EHP-101 Concludes with Positive Safety Results

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Rituximab Helps Reverse Boy’s MS, Top Secondary DMTs in Europe, Tricking Remyelination, Early MS Treatment Strategies

Lemtrada, News Link Between Lemtrada, Mortality More Common Than Previously Reported

News Persistent MS-related Fatigue Linked to Damage in Specific Brain Regions, Study Finds

A Life in Letters -- A Column By Jamie Hughes, Columns I Am Grateful for Everything — Even MS

Columns, Fall Down, Get Up Again- a Column by John Connor Life Is Better with a Local MS Nurse

Columns, The MS Wire - A Column by Ed Tobias Are Your MS Disease-modifying Treatments Old School or New School?

News Rituximab Leads to ‘Dramatic’ Recovery in Boy with Aggressive RRMS, Case Study Reports

News NIH Grants $130K for Research to Improve Sleep of MS Patients

Columns, MS in Moderation, a column by Tamara Sellman Need to Know: The Hug You Never Want to Receive

Columns, Silver Linings - a Column by Jennifer Powell I Will Not Be Sidelined in the Game of Life

News Lack of Progressive MS Treatments Has Several Causes, But Advances are Promising, Reviewers Contend

News Gene on X Chromosome May Be Reason Women at Higher Risk of MS, Study Says

Columns, MSunderstood Millennial - a Column by Stephanie Towler The Clinical Trial I Participated in Was a Positive Experience

News Immune System Molecule IL-17A Likely Inflammatory Agent in RRMS, Study Says

News Gilenya, Aubagio, Tysabri, Tecfidera Dominate MS Therapy Switches in Europe, Spherix Survey Finds

News Exploring Early Treatment Strategies for RRMS: An Interview with Neurologist Daniel Ontaneda

News In Brains Damaged by MS or Age, Cells Can Be Tricked to Promote Remyelination, Study Suggests

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Dark Rimmed Lesions, Sativex in the UK, NHS Care Toolkit for Neurological Diseases, Wahls Diet

News Imaging That Captures Damage to Brain in CIS Helps in Determining Likelihood of MS, Study Says

News NHS ‘Toolkit’ Aims to Improve Care Given People with MS, Other Neurological Ills in UK

Columns, Fall Down, Get Up Again- a Column by John Connor Up Peristeen, or How to Beat the Blockade

News Wahls Seminar Provides Different Perspectives on Managing MS: A Nutritionist’s View

Columns, The MS Wire - A Column by Ed Tobias MS Progression’s Speed Tagged to ‘Smoldering’ Brain Inflammation